April 10, 2018 / 11:29 AM / 4 months ago

BRIEF-Karyopharm's Selinexor Receives Fast Track Designation From FDA

April 10 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM’S SELINEXOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

* EXPECTS TO REPORT TOP-LINE DATA FROM STORM STUDY AT END OF APRIL 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below